A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

Key Inclusion Criteria: * Male or female at birth, aged 18-70 years, inclusive, at screening Diagnosed with SAD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), confirmed by a Mini-International Neuropsychiatric Interview (MINI) version 7.0.2 * LSAS total score of ≥70 * CGI-S score of ≥4 Key Exclusion Criteria: * Clinically predominant psychiatric diagnosis other than SAD per the MINI * Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or any current diagnosis of posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder * Reports moderately severe to severe symptoms of depression * Frequent use of benzodiazepines within 90 days of screening * Used prohibited medication or prohibited herbal or other supplements within 5 half- lives or 21 days prior to Day 1 and unwillingness to refrain from their use for the duration of the trial * Recent suicidal ideation or behavior * Current or recent moderate or severe substance use disorder as assessed by the MINI * Is unwilling/unable to abstain from alcohol, marijuana, THC, CBD, and/or any other psychoactive substances (except for nicotine or caffeine) for the duration of the trial, per Investigator judgment, and/or has a positive alcohol test or drug test at Screening or Day 1 * Clinically significant abnormal findings in safety assessments * Has significant progressive disorders or unstable medical condit…